Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
Lee YG, Kang EJ, Keam B, Choi JH, Kim JS, Park KU, Lee KE, Kim HJ, Lee KW, Kim MK, Ahn HK, Shin SH, Kim HR, Kim SB, Yun HJ. Lee YG, et al. Among authors: kim sb, kim hj, kim js, kim hr, kim mk. Cancer Res Treat. 2022 Jan;54(1):109-117. doi: 10.4143/crt.2020.1329. Epub 2021 Apr 27. Cancer Res Treat. 2022. PMID: 33940788 Free PMC article.
Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.
Kim I, Yoon SS, Lee KH, Keam B, Kim TM, Kim JS, Kim HG, Oh MD, Han KS, Park MH, Park S, Kim BK. Kim I, et al. Among authors: kim hg, kim tm, kim js, kim bk. Clin Transplant. 2006 Jul-Aug;20(4):496-503. doi: 10.1111/j.1399-0012.2006.00512.x. Clin Transplant. 2006. PMID: 16842528 Clinical Trial.
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Han HS, Kim JS, Park JH, Jeon YK, Lee KW, Oh DY, Kim JH, Park SY, Im SA, Kim TY, Park IA, Bang YJ. Han HS, et al. Among authors: kim ty, kim js, kim jh. J Korean Med Sci. 2009 Oct;24(5):910-7. doi: 10.3346/jkms.2009.24.5.910. Epub 2009 Sep 24. J Korean Med Sci. 2009. PMID: 19794992 Free PMC article.
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Park S, Keam B, Kim SH, Kim KH, Kim YJ, Kim JS, Kim TM, Lee SH, Kim DW, Lee JS, Heo DS. Park S, et al. Among authors: kim yj, kim dw, kim sh, kim js, kim tm, kim kh. Cancer Res Treat. 2015 Oct;47(4):630-7. doi: 10.4143/crt.2014.244. Epub 2015 Feb 16. Cancer Res Treat. 2015. PMID: 25687850 Free PMC article.
Current Status and Challenges of Cancer Clinical Trials in Korea.
Shim BY, Park SH, Lee S, Kim JS, Lee KE, Kang YK, Ahn MJ. Shim BY, et al. Among authors: kim js. Cancer Res Treat. 2016 Jan;48(1):20-7. doi: 10.4143/crt.2014.317. Epub 2015 Mar 2. Cancer Res Treat. 2016. PMID: 25761486 Free PMC article.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Mok TS, et al. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.
15,738 results
You have reached the last available page of results. Please see the User Guide for more information.